Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
954 studies found for:    "Follicular lymphoma"
Show Display Options
Rank Status Study
1 Recruiting Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Conditions: Follicular Lymphoma;   Follicular Non-Hodgkin´s Lymphoma;   Autologous Effector Lymphocytes
Intervention: Biological: Autologous effector lymphocytes expanded ex-vivo
2 Completed Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Follicular Lymphoma;   Chronic Lymphocytic Leukemia;   Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
Intervention: Drug: ofatumumab
3 Suspended Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
Conditions: Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ibrutinib;   Biological: Rituximab;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
4 Recruiting Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Conditions: Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: Ofatumumab;   Drug: Bendamustine Hydrochloride;   Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent;   Radiation: Fludeoxyglucose F-18
5 Active, not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
6 Active, not recruiting
Has Results
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: rituximab;   Drug: lenalidomide
7 Terminated Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
Conditions: Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: oblimersen sodium;   Biological: rituximab;   Other: laboratory biomarker analysis
8 Active, not recruiting Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)
Condition: Lymphoma, Follicular
Intervention:
9 Completed Autologous Vaccine for Follicular Lymphoma
Condition: Lymphoma, Follicular
Intervention: Biological: Autologous FL vaccine
10 Terminated An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Drug: Bortezomib;   Drug: Rituximab
11 Unknown  Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
Condition: Lymphoma, Follicular
Intervention:
12 Completed Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
Condition: Lymphoma, Follicular
Intervention: Drug: HuMax-CD20
13 Terminated
Has Results
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Drug: Bortezomib;   Drug: Rituximab;   Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Dexamethasone
14 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Conditions: Lymphoma, Follicular;   Stem Cell Transplantation
Intervention: Drug: Reduced_intensity conditioning
15 Recruiting Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab;   Biological: Rituximab
16 Recruiting Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab-CHOP;   Drug: Rituximab-CVP;   Drug: Rituximab-Bendamustine
17 Completed Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Conditions: B Cell Lymphoma;   Follicular Lymphoma;   Neoplasm
Interventions: Drug: Id-KLH Vaccine;   Drug: QS-21 (Stimulation-QS-21) Drug
18 Active, not recruiting Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Condition: Recurrent Follicular Lymphoma
Interventions: Drug: idelalisib;   Drug: lenalidomide
19 Recruiting Idiotypic Vaccination for Follicular Lymphoma Patients
Conditions: Follicular Lymphoma;   First Relapse/Progression
Intervention: Biological: Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
20 Completed Randomized Study for Patients With Follicular Lymphoma Needing Treatment
Condition: Follicular Lymphoma
Interventions: Procedure: CHVP + interferon;   Drug: fludarabine;   Procedure: CHOP + TBI and autotransplant

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years